AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 271 min read$CW

Watts John C sold $641K of CW

Watts John C (EVP & Chief Growth Officer) sold 1,035 shares of CURTISS WRIGHT CORP (CW) at $619.46 ($0.64M total) on 2026-08-27.

Original reporting
SEC EDGAR · Watts John C
Published Aug 27, 2026, 8:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 27, 2026, 9:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CW
Neutral
medium confidence
Mentioned
$CW
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CWNeutralLow
01

Why it matters

Provides fresh data on insider holdings, useful for short-term sentiment assessment.

02

Market read

Insider sale adds to monitoring of executive confidence but unlikely to move market alone.

03

What to watch

Potential upcoming corporate actions or personal tax considerations.

Relevance 5/10Novelty 4/10Timing: same-day filing

Background

Form 4 filing discloses insider transactions required by SEC.

Company-level read

Ticker impact

$CWNeutralMedium confidence
Context

EVP & Chief Growth Officer John Watts sold 1,035 shares for $641,141, reducing his stake to 2,736 shares.

Expected impact

Potential short-term downward pressure on CW stock.

Evidence & confidence

Sale size is modest relative to market cap; impact likely limited but could influence sentiment.

Market effects

Sector

Minimal effect on aerospace & defense sector.

Regional

No significant regional impact.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

Sale could be routine liquidity need, not a negative signal.

Key entities

  • Company
    Curtiss-Wright Corp

    Aerospace and industrial manufacturer listed on NYSE.

  • Executive
    John Watts

    EVP & Chief Growth Officer at Curtiss-Wright.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CW insider trading history →

Related articles

SEP 22
$CWMed

Curtiss-Wright Slides As Investors Question CEO Handoff

Curtiss-Wright (CW) shares fell as investors reacted to a planned leadership transition, with the current COO set to become CEO in 2027. Concerns about strategic continuity and execution risk were raised, despite the company's strong financial position and growth prospects. Quarterly results may be volatile due to cash conversion and supply chain pressures.

tipranks.com1 min
SEP 22
$CWMedAI 8/10

Why is Curtiss-Wright stock sliding today?

Curtiss-Wright stock fell 4.0% after announcing CEO Lynn M. Bamford will transition to Executive Chair, with COO Kevin M. Rayment succeeding in 2027. The change introduced strategic uncertainty, and the stock is near a 52-week low of $544.64, below its high of $808.16. The ex-dividend date is also approaching, adding to the pressure.

investing.com2 min
SEP 15
$CWMed

CW Initiated Coverage by Guggenheim -- Rating Upgraded to Buy

Guggenheim initiated coverage on Curtiss-Wright (CW) with a 'Buy' rating and a $786.00 price target. The stock is currently trading at $551.21, which is 24.3% above its GF Value™ of $443.58, indicating overvaluation. CW has a GF Score™ of 94/100, reflecting strong performance in growth and profitability, but a valuation rank of 5/10. Insider activity shows net selling of $705,928 over the last three months.

gurufocus.com2 min
SEP 6
$CWMed

Curtiss Wright (CW) Wins New Defense Work, Is The Stock Cheap After The Selloff?

Curtiss-Wright (CW) secured $40M in contracts for the U.S. Army's air defense system. Its stock is down 24.3% over 30 days, but up 17.8% over 1 year. Analysts debate its valuation, with some seeing it as undervalued at $566.75, citing strong backlog growth and growth projections. The company trades at a P/E of 38.7x, lower than peers but higher than its own fair ratio of 24.8x.

simplywall.st3 min
SEP 2
$CWMed

Piper Sandler initiates Curtiss-Wright stock at neutral on valuation

Piper Sandler initiated coverage on Curtiss-Wright (NYSE:CW) with a Neutral rating and $665 price target, citing valuation concerns. The company reported Q2 earnings beating EPS estimates but missing on revenue. Curtiss-Wright's order book is up 12% YTD, and it raised its full-year outlook. Piper Sandler notes the stock's multiple expansion and potential overvaluation.

investing.com2 min
SEP 1
$CWHighAI 8/10

Curtiss-Wright reports strong Q2 2026 results and raises full-year guidance across defense, nuclear and industrial markets

Curtiss-Wright reported Q2 2026 sales of $924M, adjusted EPS of $3.72, and adjusted operating margin of 19.4%, all above expectations. The company raised full-year guidance to 8-9% sales growth and 14-16% EPS growth, with free cash flow outlook at $585M-$605M. New orders increased 8% YoY to $1.1B, and backlog reached $4.5B, up 10% from year-end 2025.

bicmagazine.com1 min